Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 2Active not recruiting 2Suspended 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Specimen Handling 16Biopsy 11Magnetic Resonance Spectroscopy 10Taxes 4Bevacizumab 4Cyclophosphamide 3Cetuximab 3olaparib 2decitabine and cedazuridine drug combination 2Vincristine 2Prednisone 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2(225)Ac-DOTA-c(RGDyK) 2zimberelimab 1zanubrutinib 1trastuzumab deruxtecan 1taletrectinib 1spartalizumab 1sotigalimab 1relatlimab 1regorafenib 1prednylidene 1neratinib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × ALT-803 × 30 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡